...
首页> 外文期刊>Stem cells international >Intracoronary Infusion of Autologous CD133~+ Cells in Myocardial Infarction and Tracing by Tc99m MIBI Scintigraphy of the Heart Areas Involved in Cell Homing
【24h】

Intracoronary Infusion of Autologous CD133~+ Cells in Myocardial Infarction and Tracing by Tc99m MIBI Scintigraphy of the Heart Areas Involved in Cell Homing

机译:Tc99m MIBI闪烁显像法检测心肌梗死中自体CD133〜+细胞的冠状动脉灌注和涉及细胞归巢的心脏区域的示踪

获取原文
获取原文并翻译 | 示例
           

摘要

CD133 mesenchymal cells were enriched using magnetic microbead anti-CD133 antibody from bone marrow mononudear cells (BMMNCs). Flow cytometry and immunocytochemistry analysis using specific antibodies revealed that these cells were essentially 89 ± 4% CD133~+ and 8 ± 5% CD34~+. CD133+/CD34~+ BMMNCs secrete important bioactive proteins such as cardiotrophin-1, angiogenic and neurogenic factors, morphogenetic proteins, and proinflammatory and remodeling factors in vitro. Single intracoronary infusions of autologous CD133+/CD34~+ BMMNCs are effective and reduce infarct size in patients as analyzed by Tc99m MIBI myocardial scintigraphy. The majority of patients were treated via left coronary artery. Nine months after cell therapy, 5 out of 8 patients showed a net positive response to therapy in different regions of the heart. Uptake of Tc99 isotope and revitalization of the heart area in inferoseptal region are more pronounced (P = 0.016) as compared to apex and anterosptal regions after intracoronary injection of the stem cells. The cells chosen here have the properties essential for their potential use in cell therapy and their homing can be followed without major difficulty by the scintigraphy. The cell therapy proposed here is safe and should be practiced, as we found, in conjunction with scintigraphic observation of areas of heart which respond optimally to the infusion of autologous CD133~+/CD34~+BMMNCs.
机译:使用来自骨髓单核细胞(BMMNCs)的磁性微珠抗CD133抗体富集CD133间充质细胞。使用特异性抗体的流式细胞术和免疫细胞化学分析显示,这些细胞基本上是89±4%CD133〜+和8±5%CD34〜+。 CD133 + / CD34〜+ BMMNCs在体外分泌重要的生物活性蛋白,如心肌营养蛋白1,血管生成和神经生成因子,形态发生蛋白以及促炎和重塑因子。 Tc99m MIBI心肌闪烁显像分析表明,单次冠状动脉内自体CD133 + / CD34〜+ BMMNCs输注有效并减少了患者的梗塞面积。大多数患者通过左冠状动脉治疗。细胞治疗后9个月,八分之八的患者在心脏的不同部位对治疗表现出了净阳性反应。与冠状动脉内注射干细胞后的顶点和前椎骨区域相比,ept下区域中Tc99同位素的吸收和心脏区域的恢复更为显着(P = 0.016)。此处选择的细胞具有其在细胞治疗中的潜在用途所必需的特性,并且闪烁扫描可以很容易地追踪其归巢。我们发现,这里提出的细胞疗法是安全的,应该结合心电图观察对自体CD133〜+ / CD34〜+ BMMNCs的输注有最佳反应的心脏区域进行实践。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号